<DOC>
	<DOCNO>NCT00486187</DOCNO>
	<brief_summary>The purpose ROSITEL study ass effect rosiglitazone , compare standard oral therapy diabetes ( metformin/sulfonylurea ) , inflammatory marker adipokine level diabetic patient use angiotensin receptor blocker ( ARB ) . We hypothesize ARB-treated diabetic patient receive rosiglitazone experience great reduction vascular inflammation level leptin resistin , associate increase adiponectin level , compare metformin/sulfonylurea regimen , benefit result part , great improvement insulin sensitivity rosiglitazone group .</brief_summary>
	<brief_title>Effects ROSIglitazone Inflammatory Markers Adipokines Diabetic Patients Using Angiotensin Receptor Blocker ( TELmisartan ) - The ROSITEL Study</brief_title>
	<detailed_description>Type 2 diabetes chronic progressive disease strongly associate all-cause cardiovascular mortality . The United Kingdom Prospective Diabetes Study ( UKPDS ) demonstrate glycemic control alone modestly reduce risk macrovascular disease among type 2 diabetic patient . Insulin resistance , identify important underlying associate factor pathogenesis type 2 diabetes , main propose mechanism responsible accelerated atherosclerosis note population . Evidence continue accumulate support role chronic subclinical vascular inflammation central component development atherosclerosis , insulin resistance type 2 diabetes . Markers subclinical inflammation , particular C-reactive protein ( CRP ) interleukin-6 ( IL-6 ) , show independent predictor diabetes cardiovascular risk . More recently , visceral adipocyte recognize produce number metabolically hormonally active substance , collectively call adipokines . The adipokine adiponectin may antiatherogenic anti-inflammatory property . High level adiponectin seem associate protection type 2 diabetes atherosclerosis via anti-inflammatory pathway . Unlike adiponectin , leptin resistin examples adipokines seem associate development atherosclerosis insulin resistance . Rosiglitazone thiazolidinedione drug approve treatment type 2 diabetes . As nuclear peroxisome proliferator-activated receptor-γ agonist , rosiglitazone reduces insulin resistance , thereby sensitize liver , muscle , adipose tissue action circulate insulin . Treatment rosiglitazone demonstrate favourably modify level inflammatory biomarkers adipokines , attenuate endothelial dysfunction , reduce coronary event follow percutaneous coronary intervention . Diabetes hypertension co-exist approximately 75 % patient combination synergistically augment cardiovascular risk . In fact , blood pressure control seem great importance prevention macrovascular disease glycemic control . Therefore , patient diabetes , dual target insulin resistance blood pressure essential reduce overall atherosclerotic risk . Recent evidence suggest angiotensin receptor blocker ( ARB ) addition antihypertensive efficacy may directly improve insulin sensitivity . These unique attribute ARB 's may prove particularly beneficial combine insulin sensitizer , rosiglitazone , treatment diabetic patient . The rationale therefore ROSITEL study compare effect rosiglitazone usual therapy adipokine level , inflammatory marker , insulin sensitivity ARB-treated diabetic patient suboptimal glycemic control .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Type 2 diabetes Hemoglobin A1c ( HbA1c ) level great equal 0.075 Treatment naïve ( current oral antidiabetic therapy ) monotherapy either metformin sulfonylurea Must meet one follow : Already angiotensin receptor blocker ( ARB hypertension and/or microalbuminuria OR If ARB : SBP &gt; 129 mm Hg and/or DBP &gt; 79 mm Hg And/Or albumin creatinine ratio ( ACR ) &gt; 2.0 mg/mmol men &gt; 2.8 mg/mmol woman Women pregnant , breast feeding , use reliable method contraception Clinical sign congestive heart failure measure leave ventricular ejection fraction &lt; 40 % Hemodynamically significant valvular heart disease hypertrophic obstructive cardiomyopathy Insulindependent diabetes mellitus Use PPARỵ agonist ( Rosiglitazone Pioglitazone ) Renal dysfunction ( creatinine &gt; 1.8 x ULN ) Hepatic disease ( liver function test &gt; 1.5 x ULN [ upper limit normal ] ) Other significant laboratory abnormality investigator feel may compromise patient 's safety participation study History systemic inflammatory disease ( rheumatoid arthritis , inflammatory bowel disease , systemic lupus erythematous ) , myositis/myopathic process , cancer ) HIV Use steroid chemotherapy drug within past year chronic use nonsteroidal antiinflammatory drug besides aspirin ( use &gt; 2 week within past year ) ; Patients potassium sparingdiuretics Treatment exclude medication prior time randomization Known hypersensitivity Rosiglitazone , ARB 's Participation another clinical study concurrently within 30day phase prior screen entry present study Unwilling provide write informed consent study participant and/or Unreliability study participant base investigator 's prior knowledge patient , inability willingness participate complete study presence concurrent physical psychological disorder may make impractical patient participate complete study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Thiazolidinediones</keyword>
	<keyword>Rosiglitazone</keyword>
	<keyword>Adipokine</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Cardiometabolic risk</keyword>
	<keyword>Angiotensin receptor blocker</keyword>
</DOC>